Practical Ring-Opening Strategy for the Sequence Determination of Cyclic Peptides from One-Bead-One-Compound Libraries

peer-reviewed · ACS Combinatorial Science · 2013

peer-reviewed · ACS Combinatorial Science · 2013. Xinxia Liang et al. The use of cyclic peptides in one-bead-one-compound libraries is limited by difficulties in sequencing hit…
Date 2013-10-14
Type peer-reviewed
Venue ACS Combinatorial Science
Publisher American Chemical Society (ACS)
Contribution adjacent
DOI 10.1021/co4000979
Citations (OpenAlex) 20

Abstract

The use of cyclic peptides in one-bead-one-compound libraries is limited by difficulties in sequencing hit compounds. Lacking a free N-terminal amine, such peptides cannot be sequenced by the Edman degradation approach, and complex fragmentation patterns are obtained by tandem mass spectrometry. To overcome this problem, we designed an alternative approach introducing a methionine residue within the macrocycle and as a linker to allow simultaneous ring-opening and release from the resin upon treatment with cyanogen bromide. The methionine linker was inverted relative to the peptide chain to allow the synthesis of cyclic peptides anchored by a lysine side chain and to avoid the presence of two C-terminal homoserine lactones on the released linear peptides. After MALDI-TOF MS/MS analysis, the peptides released from a single bead were sequenced manually and with a de novo sequencing software. The strategy described herein is compatible with commonly used amino acids and allows sequencing of cyclic peptides in one-bead-one-compound libraries, thus reducing the need for encoding.

Authors

  1. Xinxia Liang · Centre hospitalier universitaire de Québec, Université Laval
  2. Anick Girard · Centre hospitalier universitaire de Québec, Université Laval
  3. Eric Biron · Centre hospitalier universitaire de Québec, Université Laval

Methods and tools

  • CNBr ring-opening of cyclic OBOC peptides: Places methionine in the macrocycle and linker so cyanogen bromide linearises and releases cyclic library peptides, which are then sequenced manually and with de novo software.

Methods it uses

  • PEAKS: Commercial DP-based de novo

Seen in the charts

Back to the full map

Back to top